Evidence map›Paper›PMID 33053430›Full record

ArticleNeurobiology of disease2020

The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier.

Tetyana P Buzhdygan, Brandon J DeOre, Abigail Baldwin-Leclair, Trent A Bullock, Hannah M McGary, Jana A Khan, Roshanak Razmpour, Jonathan F Hale, Peter A Galie, Raghava Potula and 2 more

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 305 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
305citing papers in PubMed, 3 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

305 citing papers in PubMed, 3 syntheses or guidelines pooled it, 501 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

245 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Tetyana P BuzhdyganDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America; Center for Substance Abuse Research, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America.
Brandon J DeOreDepartment of Biomedical Engineering, Rowan University, Glassboro, NJ 08028, United States of America.
Abigail Baldwin-LeclairDepartment of Biomedical Engineering, Rowan University, Glassboro, NJ 08028, United States of America.
Trent A BullockDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America; Center for Substance Abuse Research, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America.
Hannah M McGaryDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America.
Jana A KhanDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America.
Roshanak RazmpourDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America.
Jonathan F HaleDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America.
Peter A GalieDepartment of Biomedical Engineering, Rowan University, Glassboro, NJ 08028, United States of America.
Raghava PotulaDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America; Center for Substance Abuse Research, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America.
Allison M AndrewsDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America; Center for Substance Abuse Research, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America.
Servio H RamirezDepartment of Pathology and Laboratory Medicine, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America; Center for Substance Abuse Research, The Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States of America; The Shriners Hospitals Pediatric Research Center, Philadelphia, PA 19140, United States of America. Electronic address: servio@temple.edu.
Temple University · USRowan University · USTemple University Hospital · US

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI Anjali M Rajadhyaksha · 2000 to 2026
$34.6M
LABORATORY OF DEVELOPMENTAL BIOLOGYR24HD000836 · NICHD · UNIVERSITY OF WASHINGTON · PI Ian Amos Glass · 1995 to 2026
$16.9M
TRAINING PROGRAM: DRUGS OF ABUSE RELATED NEUROPEPTIDEST32DA007237 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ELLEN M UNTERWALD · 1988 to 2026
$10.6M
Brain endothelial EVs role in the neuropathology of drugs of abuse and HIVR01DA046833 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI POTULA, RAGHAVA, RAMIREZ, SERVIO HEYBERT · 2018 to 2022
$2.6M
Role of Patrolling Monocytes in Cerebral Vascular Repair during HIV/Substance AbuseK01DA046308 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ANDREWS, ALLISON MICHELLE · 2019 to 2023
$749k
NICHD NIH HHS R24 HD000836NIDA NIH HHS K01 DA046308NIDA NIH HHS P30 DA013429NIDA NIH HHS R01 DA046833NIDA NIH HHS T32 DA007237
6 · The paper itself

Abstract

As researchers across the globe have focused their attention on understanding SARS-CoV-2, the picture that is emerging is that of a virus that has serious effects on the vasculature in multiple organ systems including the cerebral vasculature. Observed effects on the central nervous system include neurological symptoms (headache, nausea, dizziness), fatal microclot formation and in rare cases encephalitis. However, our understanding of how the virus causes these mild to severe neurological symptoms and how the cerebral vasculature is impacted remains unclear. Thus, the results presented in this report explored whether deleterious outcomes from the SARS-CoV-2 viral spike protein on primary human brain microvascular endothelial cells (hBMVECs) could be observed. The spike protein, which plays a key role in receptor recognition, is formed by the S1 subunit containing a receptor binding domain (RBD) and the S2 subunit. First, using postmortem brain tissue, we show that the angiotensin converting enzyme 2 or ACE2 (a known binding target for the SARS-CoV-2 spike protein), is ubiquitously expressed throughout various vessel calibers in the frontal cortex. Moreover, ACE2 expression was upregulated in cases of hypertension and dementia. ACE2 was also detectable in primary hBMVECs maintained under cell culture conditions. Analysis of cell viability revealed that neither the S1, S2 or a truncated form of the S1 containing only the RBD had minimal effects on hBMVEC viability within a 48 h exposure window. Introduction of spike proteins to invitro models of the blood-brain barrier (BBB) showed significant changes to barrier properties. Key to our findings is the demonstration that S1 promotes loss of barrier integrity in an advanced 3D microfluidic model of the human BBB, a platform that more closely resembles the physiological conditions at this CNS interface. Evidence provided suggests that the SARS-CoV-2 spike proteins trigger a pro-inflammatory response on brain endothelial cells that may contribute to an altered state of BBB function. Together, these results are the first to show the direct impact that the SARS-CoV-2 spike protein could have on brain endothelial cells; thereby offering a plausible explanation for the neurological consequences seen in COVID-19 patients.

Indexed as

Angiotensin-Converting Enzyme 2Blood-Brain BarrierCapillary PermeabilityCell Adhesion MoleculesCell SurvivalCOVID-19DementiaElectric ImpedanceEndothelial CellsFrontal LobeHumansHypertensionInflammationIntercellular JunctionsInterleukin-6In Vitro TechniquesACE2 protein, humanAngiotensin-Converting Enzyme 2Cell Adhesion MoleculesIL6 protein, humanInterleukin-6Matrix MetalloproteinasesProtein SubunitsRNA, MessengerSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Blood-brain barrierCerebral vascular biologyCOVID-19Microfluidic chipNeuroinflammationSARS-CoV-2Tissue engineering

Identifiers

PMID33053430
PMCPMC7547916
OpenAlexW3092499620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.